Fixed topical combinations in glaucomatous patients and ocular discomfort

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 13, 2012, Pages 1829-1835

  Nebbioso, Marcella ^a   Evangelista, Mariasilvia ^a   Librando, Aloisa ^a   Di Blasio, Dario ^b   Pescosolido, Nicola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Medical Centre Principal Villafranca (VR)   (Italy)

Author keywords

Brinzolamide timolol; Discomfort ocular; Dorzolamide timolol; Fixed topical combination; Glaucoma

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZALKONIUM CHLORIDE; BRINZOLAMIDE PLUS TIMOLOL; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; FLUORESCEIN;

ADULT; AGED; ARTICLE; BLINKING; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DRUG STABILITY; DRUG TOLERABILITY; EYE DISCOMFORT; EYE EXAMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR PROTECTION INDEX; OCULAR SURFACE DISEASE INDEX; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; SUSPENSION;

ADMINISTRATION, OPHTHALMIC; AGED; ANTIHYPERTENSIVE AGENTS; BENZALKONIUM COMPOUNDS; CARBONIC ANHYDRASE INHIBITORS; DRUG COMBINATIONS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; MALE; MIDDLE AGED; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SULFONAMIDES; SUSPENSIONS; THIAZINES; THIOPHENES; TIME FACTORS; TIMOLOL;

EID: 84865320014     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.705830     Document Type: Article

References (41)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7 (Pubitemid 43325451)
2. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20; discussion 829-830 (Pubitemid 34620349)
3. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56 (Pubitemid 36401765)
4. Bengtsson B, Heijl A. A long term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma 2005;14:135-8 (Pubitemid 40389182)
5. Maier PC, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134-6 (Pubitemid 41003170)
6. Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72 (Pubitemid 350016362)
7. No authors listed. The Advanced Glaucoma Intervention Study (AGIS): The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators. Am J Ophthalmol 2000;130:429-40
8. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13 (Pubitemid 34620348)
9. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8 (Pubitemid 37237370)
10. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8 (Pubitemid 40631506)
11. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007;144:533-40
12. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5 (Pubitemid 38457133)
13. Noecker RJ. The management of glaucoma and intraocular hypertension: current approaches and recent advances. Ther Clin Risk Manag 2006;2:193-206 (Pubitemid 43950056)
14. Dunn FG, Frohlich ED. Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent. Pharmacotherapy 1981;1:188-200 (Pubitemid 12066739)
15. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol 2000;44(Suppl 2):S141-5
16. Sanchez-Pulgarin M, Martinez-de-la-Casa JM, Garcia-Feijoo J, et al. Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol. Arch Soc Esp Oftalmol 2011; 86:149-53
17. Nebbioso M, De Gregorio F, Prencipe L, et al. Psychophysical and Electrophysiological Testing in Ocular Hypertension. Optom Vis Sci 2011;88:E928-39
18. Schiffman RM, Christianson MD, Gordon J, et al. Reliability and validity of the ocular surface disease index. Arch ophthalmol 2000;118:615-21 (Pubitemid 30327337)
19. Bell NP, Ramos JL, Feldman RM. Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension. Clin Ophthalmol 2010;4:1331-46
20. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. REFJ 1999;106:556-63 (Pubitemid 30191592)
21. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23 (Pubitemid 34293291)
22. Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol 2009;4:59-64
23. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
24. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-30 (Pubitemid 29109440)
25. Dogan AS, Orhan M, Soylemezoglu F, et al. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Experiment Ophthalmol 2004;32:62-6
26. Vaede D, Baudouin C, Warnet JM, et al. Preservatives in eye drops: towards awareness of their toxicity. J Fr Ophtalmol 2010;33:505-24
27. Green K, Tonjum A. Influence of various agents on corneal permeability. Am J Ophthalmol 1971;72:897-905
28. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008;115:109-15
29. Pauly A, Meloni M, Brignole-Baudouin F, et al. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci 2009;50:1644-52
30. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-6 (Pubitemid 38857008)
31. Blondin C, Hamard P, Cholley B, et al. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res 2003;27:253-9 (Pubitemid 37315485)
32. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-8 (Pubitemid 38859312)
33. Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009;147:725-35; e1
34. Ammar DA, Kahook MY. Effects of benzalkonium chloride-or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 2011;17:1806-13
35. Bensoussan L, Blondin C, Baudouin C, et al. Flow cytometric analysis of HLA-DR. IL-6 and IL-8 expression by conjunctival epithelial cells from patients with prolonged topical antiglaucoma treatments. J Fr Ophtalmol 2003;26:782-9 (Pubitemid 37351711)
36. Beckers HJ, Schouten JS, Webers CA. Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2009;3:593-9
37. Mundorf TK, Rauchman SH, Williams RD, et al. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008;2:623-8
38. Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther 2000;22:1204-12
39. Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs. placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 2004;18:905-10 (Pubitemid 39328328)
40. Rossi GC, Pasinetti GM, Sandolo F, et al. From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study. Expert Opin Pharmacother 2011;12:2425-31
41. Tsukamoto H, Noma H, Mukai S, et al. The efficacy and ocular discomfort of substituting brinzolamide for dorzolamide in combination therapy with latanoprost, timolol, and dorzolamide. J Ocul Pharmacol Ther 2005;21:395-9 (Pubitemid 41541059)